Q2 2024 EPS Estimates for Nicox S.A. Cut by Analyst (OTCMKTS:NICXF)

Nicox S.A. (OTCMKTS:NICXF) – Equities researchers at HC Wainwright dropped their Q2 2024 earnings per share (EPS) estimates for shares of Nicox in a research report issued to clients and investors on Tuesday, April 23rd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.09) per share for the quarter, down from their prior forecast of ($0.08). The consensus estimate for Nicox’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Nicox’s Q1 2024 earnings at ($0.03) EPS, Q3 2024 earnings at ($0.07) EPS and FY2024 earnings at ($0.26) EPS.

Nicox Price Performance

NICXF opened at $0.44 on Thursday. The business has a 50 day simple moving average of $0.44 and a two-hundred day simple moving average of $0.52. Nicox has a one year low of $0.44 and a one year high of $0.44.

About Nicox

Nicox SA operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.